Home Newsfeeds B of A Securities Maintains Buy on Amazon.com, Lowers Price Target to $157

B of A Securities Maintains Buy on Amazon.com, Lowers Price Target to $157

B of A Securities analyst Justin Post maintains Amazon.com (NASDAQ:AMZN) with a Buy and lowers the price target from $170 to $157.

byBenzinga Newsdesk

October 3, 2022

1 minute read

B of A Securities analyst Justin Post maintains Amazon.com (NASDAQ:AMZN) with a Buy and lowers the price target from $170 to $157.

RespireRx Signs LOI With Australian CRO For Dronabinol Development For Obstructive Sleep Apnea

By Vuk Zdinjak

November 17, 12:21 PM

RespireRx Pharmaceuticals Inc. (OTCPK:RSPI) entered into a letter of intent with an Australia headquartered bespoke clinical research organization focused on cannabinoid and psychedelic clinical research.

RSPI

Zai Lab Ltd Says National Medical Products Administration Approved Biologics License Application For Vyvgart For Treating Generalized Myasthenia Gravis

By Happy Mohamed

June 30, 9:12 AM

First-and-only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p<0.0001) during the first treatment cycle in the Phase 3 ADAPT trial

ARGX